Boehringer Ingelheim has decided not to exercise its exclusive option to license Nxera’s GPR52 agonist program for schizophrenia, including the Phase 2 ready lead compound NXE0048149. All rights to the GPR52 portfolio will revert to Nxera Pharma, offering a potential new therapeutic option for schizophrenia patients. Nxera plans to explore strategic opportunities, including partnering with a major pharmaceutical company in 2026. Despite this decision, Nxera remains optimistic about the program’s potential and is committed to advancing discussions with potential partners next year. The event reported has no impact on Nxera’s financial results for the current period.

Read more at GlobeNewswire: Nxera Pharma to Regain Full Rights to GPR52 Agonist Program